Dr. Clay Siegall has built a reputation in the world of medicine and research in Cancer therapies. He Founded of Seattle Genetics in 1998. This is a biotech firm that focuses on the development of therapy drugs for diseases.
Under his leadership, Seattle Genetics has gained great success. He has managed to develop FDA-approved antibody conjugate drug. This was the first ADC to be approved by FDA. Dr.Siegall has created a pipeline of more than 20 drugs plus high-end partnership with manufacturers like Genentech, Pfizer, and Bayer.
Dr. Clay inspiration and motivation to join the medical world began while he was young. He was also interested in medicine and the power of technology. Clay’s interest in Cancer began while he was still at the University of Maryland. After experiencing the severity of Cancer through a friend, Clay developed a keen interest in alternative treatment.
Money was a motivation, but Clay commented that the Company makes its money through the sale of their FDA-approved drugs. Seattle Genetics also generates revenue from the partnerships that they have formed over the years.
Every successful business has a marketing strategy, and so does Seattle Genetics. According to Dr. Siegall, the team spends a lot of time in meeting and dining with potential clients. They negotiate and re-negotiate. The company has a great legal team. Dr. Siegall has attributed his success to hard work, passion, and motivation to achieve the set goals.
Dr. Clay holds a Bachelor of Science in Zoology from the University of Maryland. He also holds a Ph.D. in Genetics from the Washington University.
Before co-founding Seattle Genetics, Dr. Clay worked with the Bristol-Meyers Squibb Pharmaceuticals Research Institute between 1991 and 1997. From 1988 to 1991, Dr. Clay collaborated with the National Cancer Institute.
Clay Siegall serves as a member of the Board of Directors of several organizations including Ultragenyx Pharmaceuticals, Washington Roundtable, and Alder BioPharmaceuticals.
Over the course of his career, Dr. Clay has won different awards as the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences in 2013. He is an author of over 70 publications and has over 15 patents.